Hai-Bing Lv, Qing-Yun Wu, Yu-Jiao Zhang, Sheng-Wei Quan, Ning Ma, Yu-Qing Dai, Yan Sun
{"title":"Study on the expression and prognostic relationship of <i>MYL6B</i> in liver cancer based on bioinformatics.","authors":"Hai-Bing Lv, Qing-Yun Wu, Yu-Jiao Zhang, Sheng-Wei Quan, Ning Ma, Yu-Qing Dai, Yan Sun","doi":"10.5306/wjco.v15.i9.1188","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer is a prevalent and deadly cancer type. Despite treatment advances, prognosis remains poor, with high recurrence rates. Early detection is crucial but challenging due to the disease's insidious nature. Myosin proteins play significant roles in cancer development, influencing cell migration, invasion, and tumor suppression. <i>MYL6B</i>, a myosin light chain, is involved in various cellular processes and has been associated with poor prognosis in colorectal adenocarcinoma and potential as a biomarker in breast cancer.</p><p><strong>Aim: </strong>To investigate the expression of <i>MYL6B</i> in liver hepatocellular carcinoma (LIHC) and its impact on prognosis and potential mechanisms of action using bioinformatics methods.</p><p><strong>Methods: </strong>The expression of <i>MYL6B</i> in pan-cancer and normal tissues was analyzed using the gene expression profiling interactive analysis 2 and tumor immune estimation resource databases. The expression level of <i>MYL6B</i> in LIHC tissues and its relationship with prognosis were analyzed, immunohistochemical analysis of <i>MYL6B</i> and its effect on immune cell infiltration, and the protein network were further studied.</p><p><strong>Results: </strong><i>MYL6B</i> was highly expressed in diffuse large b-cell lymphoma, LIHC, pancreatic adenocarcinoma, skin cutaneous melanoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, and lowly expressed in kidney chromophobe, acute myeloid leukemia, testicular germ cell tumors. The expression level of <i>MYL6B</i> was significantly different between cancer and normal tissues. It had a significant impact on both overall survival and disease-free survival. <i>MYL6B</i> is highly expressed in hepatocellular carcinoma and its expression level increases with cancer progression. High <i>MYL6B</i> expression is associated with poor prognosis in terms of overall survival and recurrence-free survival. The immunohistochemical level of <i>MYL6B</i> is high in hepatocellular carcinoma tissues, and <i>MYL6B</i> has a high level of immune infiltration inflammation. In protein network analysis, <i>MYL6B</i> is correlated with <i>MYL2</i>, <i>MYL6</i>, <i>MYL9</i>, <i>MYLK4</i>, <i>MYLK2</i>, <i>MYL12A</i>, <i>MYL12B</i>, <i>MYH11</i>, <i>MYH9</i> and <i>MYH10</i>.</p><p><strong>Conclusion: </strong>The expression level of <i>MYL6B</i> in LIHC was significantly higher than in normal liver tissues, and it was correlated with the degree of differentiation survival rate, and immune infiltration. <i>MYL6B</i> is a potential target for LIHC treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 9","pages":"1188-1197"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i9.1188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary liver cancer is a prevalent and deadly cancer type. Despite treatment advances, prognosis remains poor, with high recurrence rates. Early detection is crucial but challenging due to the disease's insidious nature. Myosin proteins play significant roles in cancer development, influencing cell migration, invasion, and tumor suppression. MYL6B, a myosin light chain, is involved in various cellular processes and has been associated with poor prognosis in colorectal adenocarcinoma and potential as a biomarker in breast cancer.
Aim: To investigate the expression of MYL6B in liver hepatocellular carcinoma (LIHC) and its impact on prognosis and potential mechanisms of action using bioinformatics methods.
Methods: The expression of MYL6B in pan-cancer and normal tissues was analyzed using the gene expression profiling interactive analysis 2 and tumor immune estimation resource databases. The expression level of MYL6B in LIHC tissues and its relationship with prognosis were analyzed, immunohistochemical analysis of MYL6B and its effect on immune cell infiltration, and the protein network were further studied.
Results: MYL6B was highly expressed in diffuse large b-cell lymphoma, LIHC, pancreatic adenocarcinoma, skin cutaneous melanoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, and lowly expressed in kidney chromophobe, acute myeloid leukemia, testicular germ cell tumors. The expression level of MYL6B was significantly different between cancer and normal tissues. It had a significant impact on both overall survival and disease-free survival. MYL6B is highly expressed in hepatocellular carcinoma and its expression level increases with cancer progression. High MYL6B expression is associated with poor prognosis in terms of overall survival and recurrence-free survival. The immunohistochemical level of MYL6B is high in hepatocellular carcinoma tissues, and MYL6B has a high level of immune infiltration inflammation. In protein network analysis, MYL6B is correlated with MYL2, MYL6, MYL9, MYLK4, MYLK2, MYL12A, MYL12B, MYH11, MYH9 and MYH10.
Conclusion: The expression level of MYL6B in LIHC was significantly higher than in normal liver tissues, and it was correlated with the degree of differentiation survival rate, and immune infiltration. MYL6B is a potential target for LIHC treatment.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
